Vaccine regimen fails to prevent HIV-1 infection in South Africa

Vaccine regimen fails to prevent HIV-1 infection in south africa

(HealthDay)—A canarypox-protein HIV vaccine regimen (ALVAC-HIV) plus bivalent subtype C gp120-MF59 adjuvant does not prevent HIV-1 infection among adults in South Africa, according to a study published in the March 25 issue of the New England Journal of Medicine.

Glenda E. Gray, M.B., B.Ch., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues randomly assigned 5,404 adults (median age, 24 years; 70 percent women) without HIV-1 to receive canarypox-protein HIV or placebo (2,704 and 2,700 participants, respectively) in a phase 2b-3 trial in South Africa. The vaccine regimen included injections of ALVAC-HIV at months 0 and 1 followed by ALVAC-HIV plus bivalent subtype C gp120-MF59 adjuvant booster injections at months 3, 6, 12, and 18.

The researchers found that at an interim analysis in January 2020, prespecified criteria for nonefficacy were met, and further vaccinations were subsequently halted. There was a similar incidence of adverse events in the vaccine and placebo groups. HIV-1 infection was diagnosed in 138 and 133 participants in the vaccine and placebo groups, respectively, during the 24-month follow-up (hazard ratio, 1.02; 95 percent confidence interval, 0.81 to 1.30; P = 0.84).

"Despite promising immunogenicity, this canarypox-protein HIV vaccine regimen was not efficacious in preventing the acquisition of HIV-1 infection in our trial population in South Africa," the authors write. "The high HIV-1 incidence that we observed in our trial illustrates the unrelenting aspect of the epidemic, especially among ."

The study was funded by Novartis Vaccines and Diagnostics, now part of GlaxoSmithKline Biologicals, which also contributed financially to the provision of preexposure prophylaxis to trial participants.


Explore further

Large-scale HIV vaccine trial to launch in South Africa

More information: Abstract/Full Text
Editorial (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2020 HealthDay. All rights reserved.

Citation: Vaccine regimen fails to prevent HIV-1 infection in South Africa (2021, March 25) retrieved 14 April 2021 from https://medicalxpress.com/news/2021-03-vaccine-regimen-hiv-infection-south.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
5 shares

Feedback to editors

User comments